

Clinical Commissioning Policy

CMICB_Clin061

Patellar tendinopathy (jumper's knee) injection into the patellar tendon

Category 1 Intervention – Not routinely commissioned

Contents

1. Policy statement	2
2. Exclusions	2
3. Core Eligibility Criteria	2
4. Rationale behind the policy statement.....	2
5. Summary of evidence review and references.....	3
6. Advice and Guidance.....	4
7. Monitoring and Review	6
8. Quality and Equality Analysis	6
9. Clinical Coding.....	6
Document Control.....	7

Last Reviewed: May 2025

This policy statement will be reviewed 5 years from the date of the last review unless new evidence or technology is available sooner.

1. Policy statement

- 1.1 Injections for patellar tendinopathy (Jumper's knee) are not routinely commissioned

2. Exclusions

- 2.1 None

3. Core Eligibility Criteria

- 3.1 There are several circumstances where a patient may meet a 'core eligibility criterion' which means they are eligible to be referred for this procedure or treatment, regardless of whether they meet the policy statement criteria, or the procedure or treatment is not routinely commissioned.
- 3.2 These core clinical eligibility criteria are as follows:
- Any patient who needs 'urgent' treatment will always be treated.
 - All NICE Technology Appraisals Guidance (TAG), for patients that meet all the eligible criteria listed in a NICE TAG will receive treatment.
 - In cancer care (including but not limited to skin, head and neck, breast and sarcoma) any lesion that has features suspicious of malignancy, must be referred to an appropriate specialist for urgent assessment under the 2-week rule.
NOTE: Funding for all solid and haematological cancers are now the responsibility of NHS England.
 - Reconstructive surgery post cancer or trauma including burns.
 - Congenital deformities: Operations on congenital anomalies of the face and skull are usually routinely commissioned by the NHS. Some conditions are considered highly specialised and are commissioned in the UK through the National Specialised Commissioning Advisory Group (NSCAG). As the incidence of some cranio-facial congenital anomalies is small and the treatment complex, specialised teams, working in designated centres and subject to national audit, should carry out such procedures.
 - Tissue degenerative conditions requiring reconstruction and/or restoring function e.g. leg ulcers, dehiscent surgical wounds, necrotising fasciitis.
 - For patients expressing gender incongruence, further information can be also be found in the current ICB gender incongruence policy and within the [NHS England gender services programme](https://www.england.nhs.uk/commissioning/spec-services/npc-crg/gender-dysphoria-clinical-programme/) - <https://www.england.nhs.uk/commissioning/spec-services/npc-crg/gender-dysphoria-clinical-programme/>

4. Rationale behind the policy statement

- 4.1 There are many management options for patellar tendinopathy (jumper's knee) which include exercise, oral medication and injections into the knee. However, there are no definitive guidelines currently available to direct treatment.
- 4.2 Various injectable agents have been used but high-quality evidence of efficacy is lacking. Hydrocortisone in particular should be avoided because of the risk of tendon rupture. None of the neighbouring CCGs have a policy on injections for patellar tendinopathy. Adopting a "not routinely commissioned" policy is therefore reasonable.

5. Summary of evidence review and references

- 5.1 Jumper's knee (patellar tendinopathy or tendonitis) describes persistent pain and dysfunction of the patellar tendon. It usually occurs as a response to overuse and has a multifactorial, complex pathology being more common in athletes who participate in sports which involve repetitive loading of the tendon e.g. basketball or volleyball.¹ Patients often describe a gradual onset with increasing symptoms and complain of a dull ache at the anterior, inferior knee which prevents activity. Prevalence in elite athletes in jumping sports has been reported to be between 14% – 22%. In non-elite athletes, the estimated prevalence is 8.5%.² Although frequently called tendonitis, which implies inflammation, histology shows that the condition is degenerative rather than inflammatory and is characterised by degeneration, cell death and micro-tears in the tendon along with evidence of formation of new blood vessels.³
- 5.2 Management includes resistance exercises, NSAIDs, corticosteroid and platelet rich plasma injections, topical GTN, extracorporeal shockwave therapy, low-energy laser therapy and therapeutic ultrasound. Surgery may be considered when these non-operative interventions have been unsuccessful.¹ Very few of these conservative management options are supported by RCTs⁴ and there is no consensus on the optimal method of treatment.⁵
- 5.3 Available evidence suggests that injections for patellar tendinopathy do demonstrate short-term pain relief and some functional improvement.⁶ However, it is important to bear in mind that this evidence is limited(see later) yet one of the most frequently used agents is corticosteroid injection which provides short term pain relief but this may also increase the risk of tendon rupture.⁵ As a result, corticosteroid injections are generally not recommended.^{7,8}
- 5.4 "High-volume" (up to 50ml) injections are also used and these may contain saline alone or with corticosteroids or anaesthetic agents.⁴ Injection is usually performed under image guidance and the mechanism is thought to involve disruption of any neovascularisation of the tendon. Although reduction in pain and some functional improvement has been reported, conclusions regarding efficacy are limited because of the lack of a randomised control group. Well-designed prospective studies are required to determine effectiveness and the optimal solution mixture.⁷
- 5.5 Other injections include stem cells, hyaluronic acid, and sclerosing agents together with autologous blood, platelet rich plasma and hyperosmolar dextrose.⁷⁻⁹ However, owing to lack of data, these agents are regarded as experimental until further studies have been performed. Overall, more high-quality clinical studies have been recommended to determine the effectiveness of these preparations and at which stage of patellar tendinopathy they are most effective.^{10,11}
- 5.6 There are a few (if any) national guidelines on this topic. Definitive guidelines for all types of interventions (including injections) in the treatment of patellar tendinopathy do not currently exist.^{1,12} Similarly, guidelines on the role of injections in the management of tendinopathy is limited.¹³
- 5.7 In summary patellar tendinopathy or Jumper's knee is a persistently painful and sometimes dysfunctional knee caused by a degenerative condition of the tendons. There are many management options which include exercise, oral medication and injections into the knee. However, there are no definitive guidelines currently available to direct treatment. Various injectable agents have been used but high-quality evidence of efficacy is lacking. Hydrocortisone in particular should be avoided because of the risk of tendon rupture. None of the neighbouring CCGs have a policy on injections for patellar tendinopathy. Adopting a "not routinely commissioned" policy is reasonable.

REFERENCES

1. Challoumas D, Pedret C, Biddle M, et al. Management of patellar tendinopathy: a systematic review and network meta-analysis of randomised studies. *BMJ Open Sport Exerc Med* 2021;**7**(4):e001110. doi: <https://dx.doi.org/10.1136/bmjsem-2021-001110>
2. Morton S, Chan O, King J, et al. High volume image-guided Injections for patellar tendinopathy: a combined retrospective and prospective case series. *Muscles Ligaments Tendons J* 2014;**4**(2):214-9.
3. Dan M, Phillips A, Johnston RV, et al. Surgery for patellar tendinopathy (jumper's knee). *Cochrane Database of Systematic Reviews* 2019;**9**:CD013034. doi: <https://dx.doi.org/10.1002/14651858.CD013034.pub2>
4. Loppini M, Maffulli N. Conservative management of tendinopathy: an evidence-based approach. *Muscles Ligaments Tendons J* 2011;**1**(4):134-7.
5. Schwartz A, Watson JN, Hutchinson MR. Patellar Tendinopathy. *Sports & Health* 2015;**7**(5):415-20. doi: <https://dx.doi.org/10.1177/1941738114568775>
6. Vander Doelen T, Jelley W. Non-surgical treatment of patellar tendinopathy: A systematic review of randomized controlled trials. *J Sci Med Sport* 2020;**23**(2):118-24. doi: <https://dx.doi.org/10.1016/j.jsams.2019.09.008>
7. Sisk D, Fredericson M. Taping, Bracing, and Injection Treatment for Patellofemoral Pain and Patellar Tendinopathy. *Curr Rev Musculoskelet Med* 2020;**13**(4):537-44. doi: <https://dx.doi.org/10.1007/s12178-020-09646-8>
8. Gaida JE, Cook J. Treatment options for patellar tendinopathy: critical review. *Curr Sports Med Rep* 2011;**10**(5):255-70. doi: <https://dx.doi.org/10.1249/JSR.0b013e31822d4016>
9. Larsson MEH, Kall I, Nilsson-Helander K. Treatment of patellar tendinopathy--a systematic review of randomized controlled trials. *Knee Surg Sports Traumatol Arthrosc* 2012;**20**(8):1632-46. doi: <https://dx.doi.org/10.1007/s00167-011-1825-1>
10. Nuhmani S. Injection therapies for patellar tendinopathy. *Phys Sportsmed* 2020;**48**(2):125-30. doi: <https://dx.doi.org/10.1080/00913847.2019.1671143>
11. van Ark M, Zwerver J, van den Akker-Scheek I. Injection treatments for patellar tendinopathy. *British Journal of Sports Medicine* 2011;**45**(13):1068-76. doi: <https://dx.doi.org/10.1136/bjsem.2010.078824>
12. Aicale R, Bisaccia RD, Oliviero A, et al. Current pharmacological approaches to the treatment of tendinopathy. *Expert Opinion on Pharmacotherapy* 2020;**21**(12):1467-77. doi: <https://dx.doi.org/10.1080/14656566.2020.1763306>
13. Ackermann PW, Renstrom P. Tendinopathy in sport. *Sports & Health* 2012;**4**(3):193-201.

6. Advice and Guidance

6.1 Aim and Objectives

- 6.1.1 This policy aims to ensure a common set of criteria for treatments and procedures across the region. This is intended to reduce variation of access to NHS services in different areas and allow fair and equitable treatment for all patients.
- 6.1.2 This policy relates to the commissioning of interventions which optimise clinical effectiveness and represent value for money.
- 6.1.3 This document is part of a suite of policies which the Integrated Care Board (ICB) uses to drive its commissioning of healthcare. Each policy is a separate public document in its own right but should be considered alongside all the other policies in the suite as well as the core principles outlined.
- 6.1.4 At the time of publication, the evidence presented per procedure/treatment was the most current available.

- 6.1.5 The main objective for having healthcare commissioning policies is to ensure that:
- Patients receive appropriate health treatments
 - Treatments with no or a very limited evidence base are not used; and
 - Treatments with minimal health gain are restricted.
- 6.1.6 Owing to the nature of clinical commissioning policies, it is necessary to refer to the biological sex of patients on occasion. When the terms 'men' and 'women' are used in this document (unless otherwise specified), this refers to biological sex. It is acknowledged that this may not necessarily be the gender to which individual patients identify.

6.2 Core Principles

- 6.2.1 Commissioning decisions by ICB Commissioners are made in accordance with the commissioning principles set out as follows:
- Commissioners require clear evidence of clinical effectiveness before NHS resources are invested in the treatment.
 - Commissioners require clear evidence of cost effectiveness before NHS resources are invested in the treatment.
 - Commissioners will consider the extent to which the individual or patient group will gain a benefit from the treatment.
 - Commissioners will balance the needs of an individual patient against the benefit which could be gained by alternative investment possibilities to meet the needs of the community.
 - Commissioners will consider all relevant national standards and consider all proper and authoritative guidance.
 - Where a treatment is approved Commissioners will respect patient choice as to where a treatment is delivered, in accordance with the 'NHS Choice' framework.
 - Commissioning decisions will give 'due regard' to promote equality and uphold human rights. Decision making will follow robust procedures to ensure that decisions are fair and are made within legislative frameworks.

6.3 Individual Funding Requests (Clinical Exceptionality Funding)

- 6.3.1 If any patients are excluded from this policy, for whatever reason, the clinician has the option to make an application for clinical exceptionality. However, the clinician must make a robust case to the Panel to confirm their patient is distinct from all the other patients who might be excluded from the designated policy.
- 6.3.2 The ICB will consider clinical exceptions to this policy in accordance with the Individual Funding Request (IFR) Governance Framework consisting of: IFR Decision Making Policy; and IFR Management Policy available on the C&M ICB website: <https://www.cheshireandmerseyside.nhs.uk/your-health/individual-funding-requests-ifr/>

6.4 Cosmetic Surgery

- 6.4.1 Cosmetic surgery is often carried out to change a person's appearance to achieve what a person perceives to be a more desirable look.
- 6.4.2 Cosmetic surgery/treatments are regarded as procedures of low clinical priority and therefore not routinely commissioned by the ICB Commissioner.
- 6.4.3 A summary of Cosmetic Surgery is provided by NHS Choices. Weblink: [Cosmetic procedures - NHS](#)

6.5 Diagnostic Procedures

- 6.5.1 Diagnostic procedures to be performed with the sole purpose of determining whether or not a restricted procedure is feasible should not be carried out unless the eligibility criteria are met, or approval has been given by the ICB or GP (as set out in the approval process of the patients responsible ICB) or as agreed by the IFR Panel as a clinically exceptional case.
- 6.5.2 Where a General Practitioner/Optometrlist/Dentist requests only an opinion the patient should not be placed on a waiting list or treated, but the opinion given and the patient returned to the care of the General Practitioner/Optometrlist/Dentist, in order for them to make a decision on future treatment.

6.6 Clinical Trials

- 6.6.1 The ICB will not fund continuation of treatment commenced as part of a clinical trial. This is in line with the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Declaration of Helsinki which stipulates that the responsibility for ensuring a clear exit strategy from a trial, and that those benefiting from treatment will have ongoing access to it, lies with those conducting the trial. This responsibility lies with the trial initiators indefinitely.

7. Monitoring and Review

- 7.1 This policy remains in force until it is superseded by a revised policy or by mandatory NICE guidance or other national directive relating to this intervention, or to alternative treatments for the same condition.
- 7.2 This policy can only be considered valid when viewed via the ICB website or ICB staff intranet. If this document is printed into hard copy or saved to another location, you must check that the version number on your copy matches that of the one published.
- 7.3 This policy may be subject to continued monitoring using a mix of the following approaches:
- Prior approval process
 - Post activity monitoring through routine data
 - Post activity monitoring through case note audits
- 7.4 This policy will be kept under regular review, to ensure that it reflects developments in the evidence base regarding effectiveness and value.

8. Quality and Equality Analysis

- 8.1 Quality and Equality Impact Analyses have been undertaken for this policy at the time of its review.

9. Clinical Coding

9.1 Office of Population Censuses and Surveys (OPCS)

Data not available

9.2 International classification of diseases (ICD-10)

Data not available

Document Control

Ref:	CMICB_Clin061 - Patellar tendinopathy (jumper's knee) injection into the patellar tendon
Version:	Version 0.4, May 2025
Supersedes:	Previous Clinical Commissioning Group (CCG) Policies
Author (inc Job Title):	Consultant in Public Health, NHS Midlands and Lancashire
Ratified by: (Name of responsible Committee)	ICB Board
Cross reference to other Policies/Guidance	N/A
Date Ratified:	May 2025
Date Published and where (Intranet or Website):	June 2025
Review date:	June 2030
Target audience:	All Cheshire & Merseyside ICB staff and provider organisations

Version History
Version 0.2 – January 2022 Title Change
Version 0.3 – July 2024 Re-formatting
Version 0.4 – May 2025 – This policy was part of a public engagement exercise, there was no feedback received.